About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

The aim of this work was to capture real-world evidence (RWE) from Scotland on the use of dostarlimab monotherapy for endometrial cancer, in patients previously treated with platinum-containing chemotherapy. Details of the presumptions made to identify this cohort are described in Section 2.3.1. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2918, to patients in Scotland.

The objectives were to:

  • Determine the number of patients receiving dostarlimab monotherapy, following prior platinum-containing chemotherapy for the treatment of recurrent or advanced endometrial cancer.
  • Describe the baseline characteristics of patients receiving dostarlimab monotherapy, following prior platinum-containing chemotherapy for the treatment of recurrent or advanced endometrial cancer.
  • Describe the treatment characteristics (prior SACT and treatment duration) of patients receiving dostarlimab monotherapy, following prior platinum-containing chemotherapy for the treatment of recurrent or advanced endometrial cancer.
  • Estimate overall survival (OS) from the start of dostarlimab monotherapy.

General enquiries

If you have an enquiry relating to this publication, please contact Julie Clarke at phs.cmop@phs.scot.

Media enquiries

If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.

Requesting other formats and reporting issues

If you require publications or documents in other formats, please email phs.otherformats@phs.scot.

To report any issues with a publication, please email phs.generalpublications@phs.scot.

Older versions of this publication

Versions of this publication released before 16 March 2020 may be found on the Data and Intelligence, Health Protection Scotland or Improving Health websites.

Last updated: 18 September 2026